 GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 18, 2021 GLOBE NEWSWIRE -- Applied Genetic Technologies Corporation Nasdaq: AGTC, a biotechnology company conducting human clinical trials of adeno-associated virus AAV-based gene therapies for the treatment of rare retinal diseases, today announced the addition of Yehia Hashad, MD to its Board of Directors. 